Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS

Journal of Controlled Release

Volumn 74, Issue 1-3, 2001, Pages 47-61

  Maeda, Hiroshi ^a   Sawa, Tomohiro ^a   Konno, Toshimitsu ^b  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Clinical overview; EPR effect; SMANCS

Indexed keywords

DOXORUBICIN; IODINATED POPPYSEED OIL; MITOMYCIN C; VINBLASTINE; ZINOSTATIN; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

ADENOCARCINOMA; CANCER SURVIVAL; CANCER THERAPY; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; DRUG RETENTION; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CARCINOMA; MACROMOLECULE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SIDE EFFECT; SOLID TUMOR;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MACROMOLECULAR SUBSTANCES; MALEIC ANHYDRIDES; MOLECULAR SEQUENCE DATA; PERMEABILITY; POLYSTYRENES; ZINOSTATIN;

EID: 0035816204     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(01)00309-1     Document Type: Conference Paper

References (49)

1. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
2. 3] bradykinin in ascitic fluid from a patient with gastric cancer
3. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger
4. Kallikrein-kinin in infection and cancer
5. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both nitric oxide scavenger and nitric oxide synthase inhibitor
6. Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth
7. Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloprotenases
8. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review
9. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS
10. Early phase tumor accumulation of macromolecules: A great difference in clearance rate between tumor and normal tissues
11. Tumoritropic and lymphotropic principles of macromolecular drugs
12. SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy
13. Conjugation of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo
14. Tumor tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma
15. Tumor-targeting chemotherapy by a xanthine oxidase-polymer conjugate that generates oxygen-free radicals in tumor tissue
16. A lipophilic derivative of neocarzinostatin. A polymer conjugation of an antitumor protein antibiotic
17. Conjugation of poly(styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: Pronounced improvements in pharmacological properties
18. Tailor-making of protein drugs by polymer conjugation for tumor targeting: A brief review on Smancs
19. Cancer selective macromolecular therapeutics: Tailoring of antitumor protein drugs
20. 2: Improved stability of SOD in vitro and in vivo
21. Role of natural killer cells and macrophages in the nonspecific resistance to tumors in mice stimulated with SMANCS, a polymer-conjugated derivative of neocarzinostatin
22. Interferon induction by SMANCS: A polymer-conjugated derivative of neocarzinostatin
23. Stimulation of macrophage by polyanions and its conjugated proteins and effect on cell membrane
24. Host-mediated antitumor activity induced by neocarzinostatin and its polymer-conjugated derivative SMANCS in tumor-bearing mice
25. Enhanced intestinal absorption of a hydrophobic polymer-conjugated protein drug, SMANCS, in an oily formulation
26. Binding to and internalization by cultured cells of neocarzinostatin and enhancement of its actions by conjugation with lipophilic styrene-maleic acid copolymer
27. Facilitated internalization of neocarzinostatin and its lipophilic polymer conjugate, Smancs, into cytosol in acidic pH
28. Comparison of the cytotoxic effects of the high- and low-molecular-weight anticancer agents on multidrug-resistant Chinese hamster ovary cells in vitro
29. Enhancement by verapamil of neocarzinostatin action on multidrug-resistant Chinese hamster ovary cells: Possible release of nonprotein chromophore in cells
30. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line
31. Polymer conjugates: Pharmacokinetic considerations for design and development
32. Preclinical evaluation of polymer-bound doxorubicin
33. Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: A preliminary report
34. Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium
35. Targeting chemotherapy for hepatoma: Arterial administration of anticancer drugs dissolved in Lipiodol
36. Targeted chemotherapy for unresectable primary and metastatic liver cancer
37. Use of oily contrast medium for selective drug targeting to tumor: Enhanced therapeutic effect and X-ray image
38. Tumor-targeted chemotherapy with SMANCS in Lipiodol for renal cell carcinoma: Longer survival with larger size tumors
39. A novel dosage approach for evaluation of SMANCS [poly-(styrene-co-maleyl-half-n-butylate)-neocarzinostatin] in the treatment of primary hepatocellular carcinoma
40. Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium
41. Targeting chemotherapy of hepatocellular carcinoma: Arterial administration of SMANCS/Lipiodol
42. Reduction of hepatic metastases in rabbits by administration of an oily anti-cancer agent into the portal vein
43. The routinization of intraperitoneal (intracavitary) chemotherapy and immunotherapy
44. A new approach to cancer chemotherapy: Selective enhancement of tumor blood flow with angiotensin II
45. Augmentation of tumor delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure
46. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting
47. The tumor blood vessel as an ideal target for macromolecular anticancer agents
48. Activation of neocarzinostatin by NADPH/l cytochrome P-450 reductase: Proposal of an ultimate mode of action in cells involving oxygen free radicals
49. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma